Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorIcahn School of Medicine at Mount Sinai
About this trial
The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder. Neuroimaging before and after stimulation will establish the neural correlates of recovery and allow predictions of outcomes, which will be assessed throughout the study and one month after its completion. Results could pave the way towards development of a new self-administered intervention to reduce craving when it is needed the most, enhancing recovery real-time and in the natural environment in people with cocaine addiction as generalizable to other drugs of abuse and other disorders of self-control.
Eligibility criteria
Qualifiers
Ability to understand and give informed consent
Men and women 18-60 years of age.
For women of childbearing potential, current use of a medically acceptable form of birth control
DSM-5 diagnosis of stimulant use disorder with crack/cocaine as the drug of choice
Disqualifiers
Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the MINI or autism spectrum disorder as confirmed by medical history at the screening visit
Current clinically significant or unstable medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, infectious diseases common in people with substance use disorders including Hepatitis B and C or HIV/AIDS; use of medications deemed exclusionary by the study team; or any laboratory value outside the reference range that the senior investigator team considers to be of clinical relevance
Head trauma with loss of consciousness (>30 min)
History of neurological or developmental disease of central origin including stroke, brain tumor or seizures, encompassing those symptoms associated with periods of drug withdrawal or abstinence
Trial design
Treatments tested in this trial
- Transcranial Direct Current Stimulator (tDCS)
- Cognitive Reappraisal Training
Treatment groups
120 Participants
are divided into 4 treatment groupsSponsors and collaborators
Icahn School of Medicine at Mount Sinai
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Soterix Medical
Collaborator
Source ClinicalTrials.gov